-$0.16 Earnings Per Share Expected for Marker Therapeutics, Inc. (NASDAQ:MRKR) This Quarter

Wall Street brokerages expect Marker Therapeutics, Inc. (NASDAQ:MRKR) to announce ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Marker Therapeutics’ earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Marker Therapeutics posted earnings per share of ($0.11) during the same quarter last year, which would suggest a negative year over year growth rate of 45.5%. The firm is expected to report its next quarterly earnings report on Thursday, March 11th.

On average, analysts expect that Marker Therapeutics will report full-year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.60) to ($0.58). For the next year, analysts expect that the company will post earnings of ($0.68) per share, with EPS estimates ranging from ($0.69) to ($0.66). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Marker Therapeutics.

Several research analysts have issued reports on the company. Oppenheimer restated a “buy” rating and set a $8.00 target price on shares of Marker Therapeutics in a research report on Monday, November 23rd. Zacks Investment Research upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 5th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $7.50.

Several institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP boosted its holdings in Marker Therapeutics by 376.5% in the third quarter. GSA Capital Partners LLP now owns 87,906 shares of the company’s stock valued at $132,000 after purchasing an additional 69,456 shares during the last quarter. State Street Corp boosted its holdings in Marker Therapeutics by 6.2% in the third quarter. State Street Corp now owns 562,503 shares of the company’s stock valued at $844,000 after purchasing an additional 32,832 shares during the last quarter. Jane Street Group LLC purchased a new stake in Marker Therapeutics in the third quarter valued at $37,000. Mercer Global Advisors Inc. ADV purchased a new stake in Marker Therapeutics in the third quarter valued at $34,000. Finally, Virtu Financial LLC boosted its holdings in Marker Therapeutics by 242.8% in the third quarter. Virtu Financial LLC now owns 42,227 shares of the company’s stock valued at $63,000 after purchasing an additional 29,908 shares during the last quarter. 29.42% of the stock is currently owned by hedge funds and other institutional investors.

Shares of MRKR stock opened at $2.65 on Thursday. Marker Therapeutics has a 12-month low of $1.32 and a 12-month high of $3.77. The stock’s 50-day moving average price is $2.24 and its 200-day moving average price is $1.77. The stock has a market capitalization of $127.27 million, a price-to-earnings ratio of -4.82 and a beta of 1.27.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.

See Also: What is included in the gross domestic product?

Get a free copy of the Zacks research report on Marker Therapeutics (MRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com